NasdaqCM - Nasdaq Real Time Price USD

Akari Therapeutics, Plc (AKTX)

1.1800 +0.0100 (+0.85%)
As of 11:33 AM EDT. Market Open.
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for AKTX

Recent News: AKTX

View More
Akari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024

Akari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024
GlobeNewswire 11 days ago
Akari Therapeutics Insider Ups Holding By 69% During Year

Akari Therapeutics Insider Ups Holding By 69% During Year
Simply Wall St. 24 days ago
Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights

Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights
GlobeNewswire 25 days ago
Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit

Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit
GlobeNewswire last month
Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing

Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing
GlobeNewswire 3 months ago
Akari Therapeutics to Present at Biotech Showcase 2024

Akari Therapeutics to Present at Biotech Showcase 2024
GlobeNewswire 4 months ago
Akari Therapeutics Appoints Experienced Life Sciences Entrepreneur Samir R. Patel, M.D. to Board of Directors

Akari Therapeutics Appoints Experienced Life Sciences Entrepreneur Samir R. Patel, M.D. to Board of Directors
GlobeNewswire 4 months ago
Akari Therapeutics Presents Poster on Progress in Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference

Akari Therapeutics Presents Poster on Progress in Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference
GlobeNewswire 5 months ago
Akari Therapeutics to Present a Poster on Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference

Akari Therapeutics to Present a Poster on Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference
GlobeNewswire 5 months ago
Presenting on the Emerging Growth Conference 63 Day 1 on October 4 Register Now

Presenting on the Emerging Growth Conference 63 Day 1 on October 4 Register Now
GlobeNewswire 6 months ago
Akari Therapeutics Reports First Half 2023 Financial Results and Highlights

Akari Therapeutics Reports First Half 2023 Financial Results and Highlights
GlobeNewswire 6 months ago
Akari Therapeutics to Present at Emerging Growth Conference

Akari Therapeutics to Present at Emerging Growth Conference
GlobeNewswire 6 months ago
View More

Related Tickers

PKBO Peak Bio, Inc.
0.0085
0.00%
 
XBIOW Xenetic Biosciences, Inc.
7.46
-17.11%
 
FBRX Forte Biosciences, Inc.
0.7399
+3.22%
 
XBIO Xenetic Biosciences, Inc.
4.1299
+9.55%
 
KTTA Pasithea Therapeutics Corp.
7.24
0.00%
 
VRAX Virax Biolabs Group Limited
0.6800
-3.13%
 
ACHV Achieve Life Sciences, Inc.
4.5700
-0.11%
 
TENX Tenax Therapeutics, Inc.
3.5101
+0.00%
 
PULM Pulmatrix, Inc.
2.0700
0.00%
 
ARTL Artelo Biosciences, Inc.
1.3250
-0.38%